BRANFORD, Conn., Oct. 6, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that three scientific abstracts demonstrating the use of the Company's FORE-SIGHT® Absolute Oximeter were presented at the annual conference of the American Academy of Pediatrics in San Francisco, CA, October 2-5, 2010. This meeting is the most comprehensive pediatric meeting in the world and represents the full spectrum of pediatric medical professionals and decision-makers.
The abstracts presented show the clinical utility of the using FORE-SIGHT technology to monitor preterm infants and other newborns under certain critical conditions. They demonstrate further that the unique information provided by FORE-SIGHT monitors can guide caregivers in their treatment options.
Thomas M. Patton, President and CEO of CASMED, stated, "We are pleased to report the publication of additional clinical validation of the FORE-SIGHT Absolute Oximeter. This research provides further information for clinicians on how FORE-SIGHT can assist them in managing difficult neonatal and pediatric patients."
Abstracts
Said M, Niforatos N, Rais-Bahrami K. Testing a New NIRS Method to Measure Mesenteric Oxygenation of Preterm Infants that Compensates for Meconium and Transitional Stool Interference. Children's National Medical Center and The George Washington University School of Medicine, Washington, D.C. (#10103)
Niforatos N, Said M, Rais-Bahrami K. Cerebral Oximetry Monitoring in Preterm Infants with Respiratory Distress Syndrome. Children's National Medical Center and The George Washington University School of Medicine, Washington, D.C. (#10896)
Chouthai N, Gopal SP, Graham P. Cerebral Oximetry Using Near-Infrared Spectroscopy (NIRS) in Newborns with Hypoxic Ischemic Encephalopathy (HIE) Who Qualify for Clinical Whole Body Hypothermia (WBH). Children's Hospital of Michigan / Wayne State University, Detroit, MI. (#11601)
About CASMED® - Monitoring What's Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the first cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter, the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.
The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.